Results 271 to 280 of about 38,942 (318)

Ranibizumab and digital ischemia

JMV-Journal de Médecine Vasculaire, 2018
Case report of a patient with age-related macular degeneration whose digital ischemia can most plausibly be attributed to ranibizumab.To report ranibizumab as the probable cause of digital ischemia in a patient treated for age-related macular degeneration.Single-patient case report.An 83-year-old woman with an unremarkable medical history suffered ...
R. Attal, Isabelle Lazareth, Pascal Priollet, G. Angelopoulos   +3 more
openaire   +3 more sources

Ranibizumab for Diabetic Retinopathy

Current Diabetes Reviews, 2009
Ranibizumab (Lucentis) is a Fab-Antibody with high affinity for VEGF, and is being designed to bind to all VEGF isoforms. This quality makes it a powerful drug for VEGF inhibition. Diseases of retinal and choroidal blood vessels are the most prevalent causes of moderate and severe vision loss in developed countries.
Monica Rodriguez-Fontal, Eric P. Jablon, John B. Kerrison, Virgil Alfaro   +3 more
openaire   +3 more sources

Pharmacokinetics of Intravitreal Ranibizumab (Lucentis)

Ophthalmology, 2007
To describe the pharmacokinetics of 0.5 mg of intravitreal ranibizumab (Lucentis) and to compare it with that of 1.25 mg of intravitreal bevacizumab (Avastin), using the same rabbit model.Experimental animal study.Twenty-eight Dutch-belted rabbits.One eye of each of 20 rabbits was injected with 0.5 mg of intravitreal ranibizumab. Both eyes of each of 4
Joel M. Reid, Jose S. Pulido, Sophie J. Bakri, M. K. Ezzat, Melissa R. Snyder, Ravinder J. Singh   +5 more
openaire   +3 more sources

Intravitreal ranibizumab in retinal macroaneurysm

Graefe's Archive for Clinical and Experimental Ophthalmology, 2010
To present the effect of intravitreal ranibizumab (Lucentis®) therapy in a patient suffering from retinal macroaneurysm.Case report. An 82-year-old female patient was diagnosed with retinal macroaneurysm of the inferior temporal artery with macular edema.
Heike Petersen, Andrea R. Wenkstern
openaire   +3 more sources

Ranibizumab for retinal arterial macroaneurysms

Graefe's Archive for Clinical and Experimental Ophthalmology, 2010
Dear Editor, We read with great interest the case report entitled “Intravitreal ranibizumab in retinal macroaneurysm” by Wenkstern et al. [1] regarding the effects of intravitreal ranibizumab (Lucentis®; Genentech, Inc, South San Francisco, CA, USA) as monotherapy for retinal arterial macroaneurysms (RAM).
Roberto Gallego-Pinazo, Manuel Díaz-Llopis, Sebastián Martínez-Castillo, J. Fernando Arevalo   +3 more
openaire   +3 more sources

Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry

British Journal of Ophthalmology, 2021
Background/Aims To compare the efficacy of ranibizumab (0.5 mg) with aflibercept (2 mg) in the treatment of cystoid macular oedema due to branch retinal vein occlusion (BRVO) over 12 months.
A. Hunt, V. Nguyen, C. Creuzot-Garcher, S. Alforja, P. Gabrielle, J. Zarranz-Ventura, Martin Guillemin, S. Fraser-Bell, R. P. Casaroli Marano, J. Arnold, I. McAllister, L. O’Toole, M. Gillies, D. Barthelmes, H. Mehta   +14 more
semanticscholar   +1 more source

Cost comparison of ranibizumab and bevacizumab

BMJ, 2011
Wet age related macular degeneration (AMD) is the leading cause of blindness in the UK.1 Most UK patients are treated with ranibizumab (Lucentis, Novartis), according to National Institute for Health and Clinical Excellence (NICE) guidance. The NHS pays for the first 14 injections; thereafter, the cost is reimbursed by Novartis, but the NHS still spent
Jackson, Timothy L, Kirkpatrick, Lucy
openaire   +4 more sources

Ranibizumab for myopic choroidal neovascularization

Expert Opinion on Biological Therapy, 2020
Myopic choroidal neovascularization (CNV) is one of the most vision-threatening complications in patients with pathologic myopia. Over the last decade, anti-angiogenesis therapy with anti-vascular endothelial growth factor (anti-VEGF) agents has become the standard-of-care treatment for myopic CNV and ranibizumab has been approved for treating myopic ...
Timothy Y Y Lai, Fanny Yip, Nicholas S. K. Fung, Danny Siu-Chun Ng   +3 more
openaire   +2 more sources

The ranibizumab saga of drug profiteering

BMJ, 2008
The National Institute for Health and Clinical Excellence (NICE) recently sanctioned the use of ranibizumab for age related macular degeneration, having originally concluded it would be cost effective only if limited to treating one eye, which could jeopardise functional vision.1 2 The exorbitant price …
Andrew Lee, John Radford
openaire   +3 more sources

Ranibizumab

Drugs, 2012
Ranibizumab, an intravitreally administered inhibitor of vascular endothelial growth factor (VEGF), is approved for the treatment of visual impairment associated with diabetic macular oedema (DME) in the EU. In four well designed, phase II or III trials (RESOLVE, RESTORE, RIDE and RISE), 1-2 years' treatment with ranibizumab was more effective than ...
openaire   +3 more sources